These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12707578)

  • 1. Abandoned therapies and unpublished trials in rheumatoid arthritis.
    Keystone EC
    Curr Opin Rheumatol; 2003 May; 15(3):253-8. PubMed ID: 12707578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella AC; O'Dell JR
    Curr Opin Rheumatol; 2003 May; 15(3):185-92. PubMed ID: 12707569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
    Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S19-21. PubMed ID: 24129131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abatacept].
    Iwamoto N; Kawakami A
    Nihon Rinsho; 2016 Jun; 74(6):968-73. PubMed ID: 27311187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
    Caporali R; Scirè CA; Todoerti M; Montecucco C
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
    Keyßer G
    Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301498
    [No Abstract]   [Full Text] [Related]  

  • 8. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
    Thomann U
    Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301497
    [No Abstract]   [Full Text] [Related]  

  • 9. [Early use of biological agents after first DMARD in rheumatoid arthritis--no].
    Keyßer G
    Dtsch Med Wochenschr; 2013 Sep; 138(37):1851. PubMed ID: 24006169
    [No Abstract]   [Full Text] [Related]  

  • 10. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F; Koehm M; Burkhardt H
    Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.
    Koduri GM; Mukhtyar C
    Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739
    [No Abstract]   [Full Text] [Related]  

  • 12. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimization of infliximab in patients with rheumatoid arthritis.
    Alten R; van den Bosch F
    Int J Rheum Dis; 2014 Jan; 17(1):5-18. PubMed ID: 24472261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2014 Dec; 56(1458):127-32. PubMed ID: 25519024
    [No Abstract]   [Full Text] [Related]  

  • 15. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
    Cohen SB; Cohen MD; Cush JJ; Fleischmann RM; Mease PJ; Schiff MH; Simon LS; Weaver AL
    J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reconsideration of glucocorticoid therapy for rheumatoid arthritis].
    Ichikawa Y
    Ryumachi; 2002 Dec; 42(6):859-62. PubMed ID: 12632604
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent progress in the medical treatment of rheumatoid arthritis].
    Takeuchi T
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):182-5. PubMed ID: 17379969
    [No Abstract]   [Full Text] [Related]  

  • 18. The safety of biological medicines for rheumatoid arthritis.
    Papadopoulos I; Demetzos C; Markantoni-Kyroudi S; Souliotis K
    Adv Exp Med Biol; 2015; 822():209-10. PubMed ID: 25416994
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
    Yoshida K; Radner H; Kavanaugh A; Sung YK; Bae SC; Kishimoto M; Matsui K; Okada M; Tohma S; Weinblatt ME; Solomon DH
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S28-32. PubMed ID: 24129133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Against parenteral gold therapy in rheumatoid arthritis].
    Kellner H
    Dtsch Med Wochenschr; 2011 Aug; 136(33):1677. PubMed ID: 21833892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.